Overview

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to test the possibility that a combination of three drugs, pomalidomide and everolimus with dexamethasone, may improve patient responses when compared with use of either drug alone, with dexamethasone in refractory/relapsed multiple myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
New Mexico Cancer Care Alliance
Collaborator:
Novartis
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Everolimus
Pomalidomide
Sirolimus
Thalidomide